A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension

Ambition [NCT01178073]

Description: The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.

Drug: Ambrisentan; Drug: Tadalafil

Primary Investigator: Engel

Drug/Device Information
Ambrisentan (Letairris) and Tadalafil (Adcirca) vs Ambrisentan alone vs Tadalafil alone
Must be PAH treatment naive
Randomized 2:1:1